肝硬化患者手握强度的切断点:一个多中心研究
Bárbara Chaves Santos1, Bruna Cherubini Alves2, Ana Luisa Ferreira Fonseca3
1Food Science Graduate Program, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil.
European journal of clinical nutrition
|January 14, 2025
概括
手握强度 (HGS) 截止点可以预测肝硬化患者的1年死亡率. 男性和女性的低HGS,按年龄分层,表明死亡风险增加.
科学领域:
- 肝病学和胃肠道学
- 临床医学 临床医学
- 老年病的医生 老年病的医生
背景情况:
- 肝硬化是全球死亡的一个重要原因.
- 准确的预后标记对于治疗肝硬化患者至关重要.
- 手握强度 (HGS) 是整体健康和脆弱性的新兴指标.
研究的目的:
- 建立特定的手握强度 (HGS) 截止点,以预测成年肝硬化患者的1年死亡率.
- 为了按性别和年龄组分层这些HGS截止点.
- 评估低HGS与该人群死亡风险之间的关联.
主要方法:
- 来自巴西四个参考中心的队列数据库的分析.
- 包括被诊断患有肝硬化的成年患者 (≥18岁).
- 使用灵敏度和特异性分析确定最佳的HGS截止值,按性别和年龄分层,并使用Cox回归模型进行验证.
主要成果:
- 该研究包括724名肝硬化患者;18.5%的患者在1年内死亡.
- 定义的HGS截止点:男性<60岁≤33kgf,女性<60岁≤12kgf;男性≥60岁≤22kgf,女性≥60岁≤10kgf.
- 低HGS与1年死亡率增加2.5倍的风险显著相关.
结论:
- 鉴定到的HGS切断点是肝硬化风险分层的有价值工具.
- 这些HGS值可以帮助临床医生识别患有1年死亡风险较高的患者.
- 实施HGS评估可以改善肝硬化护理中的患者管理和预后.
相关概念视频
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Cirrhosis I: Introduction
Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...
Cirrhosis II: Pathophysiology
Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...


